Locations:
Search IconSearch

Vital Stats From Our Heart Failure and Electrophysiology Programs

Our latest volume and outcomes data in two key subspecialty areas

Below we share recent volumes and clinical outcomes from two programs in Cleveland Clinic’s Miller Family Heart, Vascular & Thoracic Institute: heart failure and recovery, and electrophysiology and cardiac pacing.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

HEART FAILURE AND RECOVERY

2022 VOLUMES

66 Number of heart transplants, including 5 in pediatric patients and 1 heart/lung transplant
72 Number of left ventricular assist device (LVAD) implantations
312 Number of patient referrals for advanced heart failure

HEART TRANSPLANT

tabular chart
40% lower Best estimate of Cleveland Clinic’s risk of 1-year graft failure vs. the national average
49% lower Best estimate of Cleveland Clinic’s risk of 3-year graft failure vs. the national average
(Source: Scientific Registry of Transplant Recipients program report of 1/5/23)

LVAD IMPLANTATION

tabular chart
246 Number of LVAD implants over the past 3 years (97 in 2020, 77 in 2021, 72 in 2022), among the highest volumes in the United States
87.5% 1-year post-implant survival, primary LVADs (vs. 86.3% STS Intermacs survival)*
87.6% 1-year post-implant survival, continuous-flow LVADs for destination therapy (vs. 83.2% STS Intermacs survival)*
*For the period 7/1/21-12/31/22.
(Source: Society of Thoracic Surgeons [STS] Intermacs Quarterly Quality Assurance Report, 2022 Q4)

ELECTROPHYSIOLOGY (EP)

OVERALL VOLUME

30,926 EP lab procedure volume, 2018-2022
6,434 EP lab procedure volume, 2022

LEAD EXTRACTION

861 Lead extraction procedures, 2018-2022
95.9% Clinical success rate for lead extractions
0.12% In-hospital mortality, vs. benchmark of 1.2% (Kusumoto et al., Heart Rhythm. 2017)

ATRIAL FIBRILLATION ABLATION

6,125 Atrial fibrillation ablations, 2018-2022
1.78% Major complication rate, vs. benchmark of 2.5% (Hsu et al., J Am Coll Cardiol. 2023)

VENTRICULAR ARRHYTHMIA ABLATION

1,318 Ventricular arrhythmia ablations, 2018-2022
3.9% Major complication rate, vs. benchmark of 10% (Cronin et al., Heart Rhythm. 2020)

LEFT ATRIAL APPENDAGE OCCLUSION (LAAO)

904 Watchman™ and Amplatzer Amulet™ devices placed for LAAO procedures (inclusive of EP and interventional cases), 2018-2022
2.2% Major complication rate within 7 days of LAAO device implant, vs. benchmark of 2.7-8.7% in published trials (Boersma et al., Eur Heart J. 2016)


For more data like this, visit clevelandclinic.org/hvtioutcomes and clevelandclinic.org/e15.

Advertisement

Related Articles

healthcare worker greeting a man at his front door
Hospital-at-Home Care Model Shown Safe and Effective in Heart Failure Management

Decongestion, therapy titration and readmission rates comparable to those with traditional hospital care

abdominal organs within the human body
Advances and Dilemmas in Multiorgan Heart Transplantation

Highlights and insights from recent Cleveland Clinic experience

William Carey, MD, with patient
December 12, 2024/Digestive/Research
Hearts From Donors Infected with Hepatitis C Are Safe for Transplant, Study Shows

Findings show no increased risk in long-term outcomes

medical device deployed in the heart's left atrial appendage
LAA Occlusion Compares Favorably With Newer Oral Anticoagulants After AF Ablation

OPTION trial demonstrates significantly less bleeding risk with comparable efficacy

man with overweight next to icon of a failing heart
Obesity Plus Heart Failure: What Are Safe and Effective Weight Loss Strategies?

New papers review the data and provide guidance on antiobesity medications and other options

Watchman FLX device for LAA occlusion
Real-World Experience With WATCHMAN FLX Replicates Pivotal Trial Outcomes

Large SURPASS registry study finds LAAO device safe and effective through one year

gut microbes in the human intestine
Gut Microbial TMAO Pathway Associated With Incident Heart Failure

Metabolites from animal product substrates implicated in heart failure development in community cohorts

woman giving subcutaneous self-injection in abdomen
Can Enoxaparin Be Used as a Bridge to Warfarin for Outpatients With LVADs?

Cleveland Clinic series supports its feasibility, especially with HeartMate 3

Ad